Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report
Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer characterized by histological features resembling hepatocellular carcinoma. Surgical intervention remains the preferred treatment modality for eligible patients. However, the efficacy of neoadjuvant therapy and alternat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496342/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555078808338432 |
|---|---|
| author | Linchuan Li Linchuan Li Dexu Zhang Jiankang Zhu Jiankang Zhu Guangyong Zhang Guangyong Zhang |
| author_facet | Linchuan Li Linchuan Li Dexu Zhang Jiankang Zhu Jiankang Zhu Guangyong Zhang Guangyong Zhang |
| author_sort | Linchuan Li |
| collection | DOAJ |
| description | Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer characterized by histological features resembling hepatocellular carcinoma. Surgical intervention remains the preferred treatment modality for eligible patients. However, the efficacy of neoadjuvant therapy and alternative treatment regimens has been found to be suboptimal. Consequently, due to the high metastatic potential and unfavorable biological behavior of HAS, the prognosis for affected patients is exceedingly poor. We present a case involving a 64-year-old male diagnosed with advanced HAS, who demonstrated significant antitumor responses following a preoperative regimen of chemotherapy combined with immunotherapy, specifically utilizing oxaliplatin, S-1, and sintilimab. Over a 2-month period of neoadjuvant therapy, the patient’s serum α-fetoprotein level significantly decreased from 52,951.56 ng/mL to 241.04 ng/mL. Computed tomography scans revealed substantial tumor regression. Subsequent radical surgical intervention confirmed significant tumor shrinkage, with no evidence of lymph node metastasis upon pathological examination. This is the first report of chemotherapy combined with sintilimab in the treatment of gastric hepatoid adenocarcinoma, which may provide novel insights into the therapeutic strategy for HAS. |
| format | Article |
| id | doaj-art-464ed2b1609c4c7b85ee85081028c127 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-464ed2b1609c4c7b85ee85081028c1272025-01-08T06:11:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14963421496342Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case reportLinchuan Li0Linchuan Li1Dexu Zhang2Jiankang Zhu3Jiankang Zhu4Guangyong Zhang5Guangyong Zhang6Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong, ChinaDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Laboratory of Metabolism and Gastrointestinal Tumor, Shandong, ChinaShandong Provincial Qianfoshan Hospital, Shandong University, Shandong, ChinaDepartment of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong, ChinaDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Laboratory of Metabolism and Gastrointestinal Tumor, Shandong, ChinaDepartment of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong, ChinaDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Laboratory of Metabolism and Gastrointestinal Tumor, Shandong, ChinaHepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer characterized by histological features resembling hepatocellular carcinoma. Surgical intervention remains the preferred treatment modality for eligible patients. However, the efficacy of neoadjuvant therapy and alternative treatment regimens has been found to be suboptimal. Consequently, due to the high metastatic potential and unfavorable biological behavior of HAS, the prognosis for affected patients is exceedingly poor. We present a case involving a 64-year-old male diagnosed with advanced HAS, who demonstrated significant antitumor responses following a preoperative regimen of chemotherapy combined with immunotherapy, specifically utilizing oxaliplatin, S-1, and sintilimab. Over a 2-month period of neoadjuvant therapy, the patient’s serum α-fetoprotein level significantly decreased from 52,951.56 ng/mL to 241.04 ng/mL. Computed tomography scans revealed substantial tumor regression. Subsequent radical surgical intervention confirmed significant tumor shrinkage, with no evidence of lymph node metastasis upon pathological examination. This is the first report of chemotherapy combined with sintilimab in the treatment of gastric hepatoid adenocarcinoma, which may provide novel insights into the therapeutic strategy for HAS.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496342/fullhepatoid adenocarcinoma of stomachimmunotherapychemotherapyprogrammed cell death-ligand 1laparoscopic gastrectomygastric cancer |
| spellingShingle | Linchuan Li Linchuan Li Dexu Zhang Jiankang Zhu Jiankang Zhu Guangyong Zhang Guangyong Zhang Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report Frontiers in Immunology hepatoid adenocarcinoma of stomach immunotherapy chemotherapy programmed cell death-ligand 1 laparoscopic gastrectomy gastric cancer |
| title | Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report |
| title_full | Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report |
| title_fullStr | Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report |
| title_full_unstemmed | Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report |
| title_short | Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report |
| title_sort | hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo immunotherapy a case report |
| topic | hepatoid adenocarcinoma of stomach immunotherapy chemotherapy programmed cell death-ligand 1 laparoscopic gastrectomy gastric cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1496342/full |
| work_keys_str_mv | AT linchuanli hepatoidadenocarcinomaofthestomachwithidealresponsetoneoadjuvantchemoimmunotherapyacasereport AT linchuanli hepatoidadenocarcinomaofthestomachwithidealresponsetoneoadjuvantchemoimmunotherapyacasereport AT dexuzhang hepatoidadenocarcinomaofthestomachwithidealresponsetoneoadjuvantchemoimmunotherapyacasereport AT jiankangzhu hepatoidadenocarcinomaofthestomachwithidealresponsetoneoadjuvantchemoimmunotherapyacasereport AT jiankangzhu hepatoidadenocarcinomaofthestomachwithidealresponsetoneoadjuvantchemoimmunotherapyacasereport AT guangyongzhang hepatoidadenocarcinomaofthestomachwithidealresponsetoneoadjuvantchemoimmunotherapyacasereport AT guangyongzhang hepatoidadenocarcinomaofthestomachwithidealresponsetoneoadjuvantchemoimmunotherapyacasereport |